Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Nov 2 2022

Full Issue

With Any Luck, This Could Be The Last Year RSV Ravages Children, Families

Pfizer's announcement Tuesday that an RSV vaccine in moms-to-be was nearly 82% effective at preventing severe cases in their babies’ first months of life was welcome news after decades of setbacks and delays. The findings won't help this year's surge, but it's possible a vaccine could be available before next fall’s RSV season.

AP: Strong RSV Vaccine Data Lifts Hopes After Years Of Futility 

A tragedy in the 1960s set back the whole field. Using the approach that led to the first polio vaccine, scientists made an experimental RSV vaccine by growing the virus in a lab and killing it. But testing in children found not only was the vaccine not protective, youngsters who caught RSV after vaccination fared worse. Two died. “For a period of 20 years, even though science was advancing, nobody wanted to go near development of an RSV vaccine,” Dr. William Schaffner, an infectious disease specialist at Vanderbilt University. Even today’s modern RSV vaccine candidates were tested first in older adults, not children, he noted. (Neergaard, 11/1)

USA Today: RSV Vaccines Are 'Long Overdue,' But Here's Why That Could Soon Change

Preventing that first serious respiratory infection might also pay off later in life, said Dr. Alejandra Gurtman, vice president of vaccine R&D for Pfizer. "If you're able to avoid that damage that you have from the first infection, you may be able to have healthier lungs," potentially avoiding problems like asthma later on, she said. (Weintraub, 11/2)

The New York Times: Scientists Are Gaining On RSV, A Persistent Threat To Children

Of the three respiratory viruses Americans are grappling with this winter, two — the coronavirus and the flu — are well-known threats. The third, respiratory syncytial virus, which already has sent thousands of children to hospitals, is a mystery to many. “It is, unfortunately, one of those large killers that nobody knows about,” said Dr. Keith Klugman, who directs the pneumonia program at the Bill & Melinda Gates Foundation. (Mandavilli, 11/1)

More on the spread of RSV —

The Atlantic: The Worst Pediatric-Care Crisis In Decades

At Johns Hopkins Children’s Center, in Maryland, staff has pitched a tent outside the emergency department to accommodate overflow; Connecticut Children’s Hospital mulled calling in the National Guard. It’s already the largest surge of infectious illnesses that some pediatricians have seen in their decades-long careers, and many worry that the worst is yet to come. (Wu, 10/31)

San Francisco Chronicle: Orange County Declares Health Emergency Due To Viruses

A health emergency has been declared in Southern California’s Orange County due to rapidly spreading viral infections that are sending more children to the hospital, health officials said Tuesday. (Vaziri, Buchmann and Asimov, 11/1)

New Hampshire Public Radio: NH Hospitals See Rise In RSV Infections Among Children 

New Hampshire hospitals are seeing an early increase in cases of respiratory syncytial virus, or RSV, this year. The cold-like infection is mild for most people but sometimes causes more severe respiratory illness in infants and very young children. (Cuno-Booth, 11/1)

NPR: RSV Is Surging. Here's What To Watch For And Answers About Treatment Options

Very young children born just before or during the pandemic did not benefit from regular or early exposure to common viruses, including RSV, which would have helped build up an immunity. (Romo, 11/2)

In related news —

The Boston Globe: Hate Needles? Flu Vaccines Of The Future Could Be Skin Patches Delivered To Your Door

On Wednesday, Vaxess announced that it raised $27 million in series B funding led by the Boston biotech investor RA Capital Management. The money helped the company finally begin the first clinical trial of its technology in August. Results from the 45-person study of a flu vaccine patch are expected by the end of the year. (Cross, 11/2)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF